3 K: S5 @# o( g+ S7 @$ i4 |+ n临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:/ s2 F; _- n9 D4 z- w
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.9 D; Y% b1 s F http://www.ncbi.nlm.nih.gov/pubmed/22968184& Q3 M; ?& g. E+ ^* Z5 F